Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics

Drug Development Research

Volumn 49, Issue 1, 2000, Pages 4-16

  Guengerich, F Peter ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioavailability; Cytochrome P450; Environmental genome project; Mutagenicity assays; Polymorphisms

Indexed keywords

CYTOCHROME P450; XENOBIOTIC AGENT;

ARTICLE; BIOAVAILABILITY; BIOTRANSFORMATION; CANCER RISK; DNA POLYMORPHISM; DRUG RESEARCH; DRUG SCREENING; ENVIRONMENTAL EXPOSURE; ENZYME ANALYSIS; ENZYME MECHANISM; GENE SEQUENCE; METABOLISM; PHARMACOGENOMICS; TOXICITY; XENOBIOTIC METABOLISM;

EID: 0034106141     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(200001)49:1<4::AID-DDR2>3.0.CO;2-R     Document Type: Article

References (133)

1. Al-Waiz M, Ayesh R, Mitchell SC, Idle JR, Smith RL. 1987. A genetic polymorphism of the N-oxidation of trimethylamine in humans. Clin Pharmacol Ther 42:588-594.
2. Alexandrie AK, Sundberg MI, Seidegård J, Tornling G, Rannug A. 1994. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 15:1785-1790.
3. Armstrong RN. 1997. Glutathione transferases. In: Guengerich FP, editor. Biotransformation, vol. 3. Comprehensive toxicology. Oxford: Elsevier Science. p 307-327.
4. Aryal P, Yoshikawa K, Terashita T, Guengerich FP, Shimada T, Oda Y. 1999. Development of a new genotoxicity test system with Salmonella typhimurium OY1001/1A2 expressing human cytochrome P450 1A2 and NADPH-cytochrome P450 reductase. Mutat Res 442:113-120.
5. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. 1984. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312:169-170.
6. Bach AWJ, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC. 1988. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85:4934-4938.
7. Bailey DG. 1995. Food-drug interactions: emphasis on grapefruit juice effects. Can J Clin Pharmacol 2:10-14.
8. Barnes HJ. 1996. Maximizing expression of eukaryotic cytochrome P450s in Escherichia coli. Methods Enzymol 272:3-14.
9. Baumann E. 1876a. Über gepaarte Schwefelsäuren in Harn. Pflügers Arch Physiol 12:69-70.
10. Baumann E. 1876b. Über Sulfosäuren im Harn. Chem Ber 9:54-58.
11. Bell LC, Guengerich FP. 1997. Oxidation kinetics of ethanol by human cytochrome P450 2E1. Rate-limiting product release accounts for effects of isotopic hydrogen substitution and cytochrome b5 on steady-state kinetics. J Biol Chem 272:29643-29651.
12. Bell-Parikh LC, Guengerich FP. 1999. Kinetics of cytochrome P450 2E1-catalyzed oxidation of ethanol to acetic acid via acetaldehyde. J Biol Chem 274:23833-23840.
13. Berghard A, Gradin K, Pongratz I, Whitelaw M, Poellinger L. 1993. Cross-coupling of signal transduction pathways: the dioxin receptor mediate induction of cytochrome P-450IA1 expression via a protein kinase C-dependent mechanism. Mol Cell Biol 13:677-689.
14. Boberg EW, Liem A, Miller EC, Miller JA. 1987. Inhibition by pentachlorophenol of the initiating and promoting activities of 1′-hydroxysafrole for the formation of enzyme-altered foci and tumors in rat liver. Carcinogenesis 8:531-539.
15. Bolt HM, Kappus H, Bolt M. 1975. Effect of rifampicin treatment on the metabolism of oestradiol and 17α-ethinyloestradiol by human liver microsomes. Eur J Clin Pharmacol 8:301-307.
16. Bosron WF, Li TK, Vallee BL. 1979. Heterogeneity and new molecular forms of human liver alcohol dehydrogenase. Biochem Biophys Res Commun 91:1549-1555.
17. Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I. 1993. Genotype and phenotype of glutathione S-transferase class μ isoenzymes μ and ψ in lung cancer patients and controls. Cancer Res 53:1004-1011.
18. Burchell B, McGurk K, Brierly CH, Clarke DJ. 1997. UDP-glucuronosyltransferases. In: Guengerich FP, editor. Biotransformation, vol. 3. Comprehensive toxicology. Oxford: Elsevier Science. p 401-435.
19. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. 1989. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696-7700.
20. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. 1992. Determination of CYP1 A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127.
21. Calleja C, Pascussi JM, Mani JC, Maurel P, Vilarem MJ. 1998. The antibiotic rifampicin is a nonsteroidal ligand and activator of the human glucocorticoid receptor. Nat Med 4:92-96.
22. Caporaso N. 1996. Genetic susceptibility and the common cancers. BioMarkers 1:174-177.
23. Carver LA, LaPres JJ, Jain S, Dunham EE, Bradfield CA. 1998. Characterization of the Ah receptor-associated protein, ARA9. J Biol Chem 273:33580-33587.
24. Cashman JR. 1997. Monoamine oxidase and flavin-containing monooxygenases. In: Guengerich FP, editor. Biotransformation, vol. 3. Comprehensive toxicology. Oxford: Elsevier Science. p 69-96.
25. Cattley RC, Preston RJ. 1995. Does DNA damage play a role in rodent liver cancer induced by peroxisome proliferators? Chem Ind Inst Toxicol Activities 15:1-7.
26. Cherian MG. 1997. Metallothionein and intracellular sequestration of metals. In: Guengerich FP, editor. Biotransformation, vol. 3. Comprehensive toxicology. Oxford: Elsevier Science, p 489-503.
27. Conney AH, Miller EC, Miller JA. 1956. The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. Cancer Res 16:450-459.
28. Constable A, Varga N, Josephy PD, Guy P, Turesky RJ. 1999. Evaluation of Escherichia coli DJ4309 expressing human P450 1A2 in mutagenicity testing of complex food mixtures. Mutat Res 442:79-87.
29. Coon MJ, Ding X, Pernecky SJ, Vaz ADN. 1992. Cytochrome P450: progress and predictions. FASEB J 6:669-673.
30. Corton JC, Anderson SP, Stauber AJ, Janszen DB, Kimbell J-S, Conolly RB. 1999. Entering the era of toxicogenomics with DNA microarrays. Chem Ind Inst Toxicol Activities 19:1-9.
31. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Algrain E, Meyer UA, Steen VM, Wolf CR, Zanger UM. 1996. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201.
32. d'Errico A, Taioli E, Chen X, Vineis P. 1996. Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. BioMarkers 1:149-173.
33. Dolphin CT, Janmohamed A, Smith RL, Shephard EA, Phillips IR. 1997. Missense mutation in flavin-containing mono-oxygenase 3 gene. FMO3, underlies fish-odour syndrome. Nat Gen 17:491-494.
34. Drakoulis N, Minks T, Ploch M, Otte F, Heinemeyer G, Kampf D, Loddenkemper R, Roots I. 1986. Questionable association of debrisoquine hydroxilator phenotype and risk for bronchial carcinoma. Acta Pharmacol Toxicol 59(Suppl. 5):220.
35. Dupret J-M, Goodfellow GH, Janezic SA, Grant DM. 1994. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. J Biol Chem 269:26830-26835.
36. Edenberg HJ, Bosrou WF. 1997. Alcohol dehydrogenases. In: Guengerich FP, editor. Biotransformation, vol. 3, Comprehensive toxicology. Oxford: Elsevier Science, p 119-131.
37. Farr S, Dunn RT II. 1999. Concise review: gene expression applied to toxicology. Toxicol Sci 50:1-9.
38. Friedberg T, Wolf CR. 1996. Recombinant DNA technology as an investigative tool in drug metabolism research. Adv Drug Deliv Rev 22:187-213.
39. Garavito RM. 1996. The cyclooxygenase-2 structure: new drugs for an old target? Nat Struct Biol 3:897-901.
40. Gonzalez FJ. 1990. Molecular genetics of the P-450 superfamily. Pharmacol Ther 45:1-38.
41. Gonzalez FJ, Idle JR. 1994. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinet 26:59-70.
42. Gonzalez FJ, Meyer UA. 1991. Molecular genetics of the debrisoquinsparteine polymorphism. Clin Pharmacol Ther 50:233-238.
43. Grant DM, Josephy PD, Lord HL, Morrison LD. 1992. Salmonella typhimurium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines. Cancer Res 52:3961-3964.
44. Guengerich FP. 1987. Enzymology of rat liver cytochromes P-450. In: Guengerich FP, editor. Mammalian cytochromes P-450, vol. 1. Boca Raton, FL: CRC Press. p 1-54.
45. Guengerich FP. 1988a. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 48:2946-2954.
46. Guengerich FP. 1988b. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 33:500-508.
47. Guengerich FP. 1989. Characterization of human microsomal cytochrome P-450 enzymes. Annu Rev Pharmacol Toxicol 29:241-264.
48. Guengerich FP. 1995. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450, 2nd ed. New York: Plenum Press. p 473-535.
49. Guengerich FP. 1997a. Introduction and historical perspective. In: Guengerich FP, editor. Biotransformation, vol. 3, Comprehensive toxicology. Oxford: Elsevier Science, p 1-6.
50. Guengerich FP. 1997b. Cytochrome P450 enzymes. In: Guengerich FP, editor. Biotransformation, vol. 3, Comprehensive toxicology. Oxford: Elsevier Science, p 37-68.
51. Guengerich FP. 1997c. Biotransformation, vol. 3. Comprehensive toxicology. Oxford: Elsevier Science.
52. Guengerich FP. 1998. The environmental genome project: functional analysis of polymorphisms. Environ Health Perspect 106:365-368.
53. Guengerich FP. 2000. Metabolism of chemical carcinogens. Carcinogenesis 21:(in press).
54. Guengerich FP, Shimada T. 1991. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391-407.
55. Guengerich FP, Gillam EMJ, Shimada T. 1996. New applications of bacterial systems to problems in toxicology. Crit Rev Toxicol 26:551-583.
56. Guengerich FP, Parikh A, Johnson EF, Richardson TH, von Wachenfeldt C, Cosme J, Jung F, Strassburg CP, Manns MR, Tukey RH, Pritchard M, Fournel-Gigleux S, Burchell B. 1997. Heterologous expression of human drug-metabolizing enzymes. Drug Metab Disp 25:1234-1241.
57. Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, VandenBranden M, Wrighton SA. 1994. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab Disp 22:975-978.
58. Hammock BD, Grant DF, Storms DH. 1997. Epoxide hydrolases. In: Guengerich FP, editor. Biotransformation, vol. 3. Comprehensive toxicology. Oxford: Elsevier Science. p 283-305.
59. Higashi Y, Hiromasa T, Tanae A, Miki T, Nakura J, Kondo T, Ohura T, Ogawa E, Nakayama K, Fujii-Kuriyama Y. 1991. Effects of individual mutations in the P-450 (C21) pseudogene on the P-450 (C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency. J Biochem 109:638-644.
60. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. 1992. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52:231-238.
61. Honkakosski P, Zelko I, Sueyoshi T, Negishi M. 1998. The nuclear orphan receptor CAR-RXR heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 18:1-7.
62. Idle JR, Oates NS, Shah RR, Smith RL. 1981. Is there a genetic predisposition to phenformin-induced lactic acidosis. Br J Clin Pharmacol 11:418P-419P.
63. Janz D, Schmidt D. 1974. Anti-epileptic drugs and failure of oral contraceptives. Lancet i:1113.
64. Johnson WW, Ueng Y-F, Mannervik B, Widersten M, Hayes JD, Sherratt PJ, Ketterer B, Guengerich FP. 1997. Conjugation of highly reactive aflatoxin B1 8,9-exo-epoxide catalyzed by rat and human glutathione transferases: estimation of kinetic parameters. Biochemistry 36:3056-3060.
65. Josephy PD, DeBruin LS, Lord HL, Oak J, Evans DH, Guo Z, Dong M-S, Guengerich FP. 1995. Bioactivation of aromatic amines by recombinant human cytochrome P450 1A2 expressed in bacteria: a substitute for mammalian tissue preparations in mutagenicity testing. Cancer Res 55:799-802.
66. Josephy PD, Evans DH, Parikh A, Guengerich FP. 1998. Expression of active human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and N-acetyltransferase in Escherichia coli: metabolic activation of aromatic amine mutagens. Chem Res Toxicol 11:70-74.
67. Kaiser J. 1997. Environment institute lays plans for gene hunt. Science 278:569-570.
68. Kaminsky LS, Fasco MJ. 1992. Small intestinal cytochromes P450. Crit Rev Toxicol 21:407-422.
69. Kaminsky LS, Zhang ZY. 1997. Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74.
70. Keeney DS, Waterman MR. 1993. Regulation of steroid hydroxylase gene expression: importance to physiology and disease. Pharmacol Ther 58:301-317.
71. Keller W. 1842. Über Verwandlung der Benzoesäure in Hippursäure. Annalen 43:108-111.
72. Kellennan G, Luyten-Kellerman M, Shaw CR. 1973a. Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am J Hum Genet 25:327-331.
73. Kellerman G, Shaw CR, Luyten-Kellerman M. 1973b. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 298:934-937.
74. Kivistö KT, Neuvonen PJ, Klotz U. 1994. Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 27:1-5.
75. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Wilson TM, Zetterstörm RH, Perlmann T, Lehmann JM. 1998. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92:73-82.
76. Kluwe WM. 1994. The relevance of hepatic peroxisome proliferation in rats to assessment of human carcinogenic risk for pharmaceuticals. Regul Toxicol Pharmacol 20:170-186.
77. Kolars JC, Awni WM, Merion RM, Watkins PB. 1991. First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490.
78. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. 1982. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 42:5030-5037.
79. Kranendonk M, Mesquita P, Laires A, Vermeulen NPE, Rueff J. 1998. Expression of human cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity studies of chemical carcinogens. Mutagenesis 13:263-269.
80. Lang NP, Butler MA, Massengill J, Lawson M, Stotts RC, MaurerJensen M, Kadlubar FF. 1994. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidem Biomarker Prev 3:675-682.
81. Lapinskas PJ, Corton JC. 1997. Peroxisome proliferator-activated receptor α: central mediator of peroxisome proliferator toxicity. Chem Ind Inst Toxicol Activities 17:1-9.
82. Lehmann JM, McKee DD, Watson MA, Wilson TM, Moore JT, Kliewer SA. 1998. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016-1023.
83. Ma Q, Whitlock JP Jr. 1997. A novel cytoplasmic protein that interacts with the Ah receptor, contains tetratricopeptide repeat motifs, and augments the transcriptional response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Biol Chem 272:8878-8884.
84. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA, Eggleston JC, Boyd MR, Hines RN. 1990. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 82:1333-1339.
85. Meyer UA, Zanger UM. 1997. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269-296.
86. Miller EC, Miller JA. 1947. The presence and significance of bound amino azodyes in the livers of rats fed p-dimethylaminoazobenzene. Cancer Res 7:468-480.
87. Miller VP, Crespi CL, Ackermann JM, Stresser DM, Busby WF Jr. 1999. Novel high throughput fluorescent cytochrome P450 assays. Proc 7th Eur Int Soc Study Xenobiotics Meet Budapest (22-26 August) 14:63.
88. Mueller GC, Miller JA. 1948. The metabolism of 4-dimethylaminoazobenzene by rat liver homogenates. J Biol Chem 176:535-544.
89. Nebert DW. 1989. The Ah locus: genetic differences in toxicity, cancer, mutation, and birth defects. Crit Rev Toxicol 20:153-174.
90. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 6:1-42.
91. Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshair CA. 1999. Microarrays and toxicology: the advent of toxicogenomics. Mol Carcinogen 24:153-159.
92. Oates NS, Shah RR, Drury PL, Idle JR, Smith RL. 1982. Captoprilinduced agranulocytosis associated with an impairment of debrisoquine hydroxylation. Br J Pharmacol 14:601P.
93. Oda Y, Yamazaki H, Thier R, Ketterer B, Guengerich FP, Shimada T. 1996. A new Salmonella typhimurium NM5004 strain expressing rat glutathione S-transferase 5-5: use in detection of genotoxicity of dihaloalkanes using an SOS/umu test system. Carcinogenesis 17:297-302.
94. Ortiz de Montellano PR. 1995. Cytochrome P450: structure, mechanism, and biochemistry, 2nd ed. New York: Plenum Press.
95. Palmer CNA, Hsu MH, Griffin KJ, Rancy JL, Johnson EF. 1998. Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol 53:14-22.
96. Parikh A, Josephy PD, Guengerich FP. 1999. Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties. Biochemistry 38:5283-5289.
97. Petersen D, Lindahl R. 1997. Aldehyde dehydrogenases. In: Guengerich FP, editor. Biotransformation, vol. 3. Comprehensive toxicology. Oxford: Elsevier Science. p 97-118.
98. Philip PA, Fitzgerald DL, Cartwright RA, Peake MD, Rogers HJ. 1988. Polymorphic N-acetylation capacity in lung cancer. Carcinogenesis 9:491-493.
99. Picoult-Newberg L, Ideker TE, Pohl MG, Taylor SL, Donaldson MA, Nickerson DA, Boyce-Jacino M. 1999. Mining SNPs from EST databases. Genome Res 9:167-174.
100. Poulsen LL, Ziegler DM. 1979. The liver microsomal FAD-containing monooxygenase: spectral characterization and kinetic studies. J Biol Chem 254:6449-6455.
101. Poulsen LL, Ziegler DM. 1995. Multisubstrate flavin-containing monooxygenases: applications of mechanism to specificity. Chem Biol Interact 96:57-73.
102. Puga A, Nebert DW, McKinnon RA, Menon AG. 1997. Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Crit Rev Toxicol 27:199-222.
103. Radjendirane V, Joseph P, Lee YH, Kimura AK, Klein-Szanto AJP, Gonzalez FJ, Jaiswal AK. 1998. Disruption of the DT diaphorase (NQ01) gene in mice leads to increased menadione toxicity. J Biol Chem 273:7382-7389.
104. Remmer H. 1957. The acceleration of evipan oxidation and the demethylation of methylaminopyrine by barbiturates. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 237:296-307.
105. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. 1992. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
106. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. 1994. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4:39-42.
107. Richardson HL, Stier AR, Borsos-Nachtnebel E. 1952. Liver tumor inhibition and adrenal histologic responses in rats to which 3′-methyl-4-dimethylaminoazobenzene and 20-methylcholanthrene were simultaneously administered. Cancer Res 12:356-361.
108. Rubin K, Andersson TB, Otter C, Thompson R, Masimirembwa C. 1999. Enzyme kinetic validation of recombinant cytochrome P450 enzymes from two different expression systems and human liver microsomes. Proc 7th Eur Int Soc Study Xenobiotics Meet Budapest (Aug 22-26) 14:57.
109. Schuetz EG, Furuya KN, Schuetz JD. 1995. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275:1011-1018.
110. Shimada T, Guengerich FP. 1991. Activation of amino-α-carboline, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, and a copper phthalocyanine cellulose extract of cigarette smoke condensate by cytochrome P-450 enzymes in rat and human liver microsomes. Cancer Res 51:5284-5291.
111. Shimada T, Oda Y, Yamazaki H, Mimura M, Guengerich FP. 1994. SOS function tests for studies of chemical carcinogenesis in Salmonella typhimurium TA 1535/pSK1002, NM2009, and NM30009. In: Adolph KW, editor. Methods in molecular genetics, vol. 5. Gene and chromosome analysis. Orlando, FL: Academic Press. p 342-355.
112. Simula TP, Glancey MJ, Söderlund EJ, Dybing E, Wolf CR. 1993a. Increased mutagenicity of 1,2-dibromo-3-chloropropane and tris(2,3-dibromopropyl)phosphate in Salmonella TA100 expressing human glutathione S-transferases. Carcinogenesis 14:2303-2307.
113. Simula TP, Glancey MJ, Wolf CR. 1993b. Human glutathione S-transferase-expressing Salmonella typhimurium tester strains to study the activation/detoxification of mutagenic compounds: studies with halogenated compounds, aromatic amines and aflatoxin B1. Carcinogenesis 14:1371-1376.
114. Smith RL, Idle JR, Mahgoub AA, Sloan TP, Lancaster R. 1978. Genetically determined defects of oxidation at carbon centres of drugs. Lancet i:943-944.
115. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE. 1997. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7:361-367.
116. Stinson SC. 1997. Uncertain climate tor antihistamines. Chem Eng News 75:43-45.
117. Suzuki A, Kushida H, Iwata H, Watanabe M, Nohmi T, Fujita K, Gonzalez FJ, Kamataki T. 1998. Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocyclic amines. Cancer Res 58:1833-1838.
118. Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, Nomizo Y, Muramoto N, Kimura S, Echizen H. 1998. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8:365-373.
119. Thier R, Pemble SE, Taylor JB, Humphreys WG, Persmark M, Ketterer B, Guengerich FP. 1993. Expression of mammalian glutathione S-transferase 5-5 in Salmonella typhimurium TA1535 leads to base-pair mutations upon exposure to dihalomethanes. Proc Natl Acad Sci USA 90:8576-8580.
120. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. 1992. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 52:471-478.
121. Tzeng H-F, Laughlin LT, Lin S, Armstrong RN. 1996. The catalytic mechanism of microsomal epoxide hydrolase involves reversible formation and rate-limiting hydrolysis of the alkyl-enzyme intermediate. J Am Chem Soc 118:9436-9437.
122. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinogen 13:129-134.
123. Wandel C, Kim RB, Kajiji S, Ghebreselasie K, Leake B, Guengerich FP, Wilkinson GR, Wood AJJ. 1999. Cytochrome P450 3A inhibition by P-glycoprotein inhibitors. Cancer Res 59:3944-3948.
124. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. 1990. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 48:120-129.
125. White PA, Rasmussen JB, Blaise C. 1996. A semi-automated, microplate version of the SOS chromotest for the analysis of complex environmental extracts. Mutat Res 360:51-74.
126. Williams RT. 1947. Detoxication mechanisms. London: Wiley.
127. Woosley RL, Chen Y, Freiman JP, Gillis RA. 1993. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269:1532-1536.
128. Wormhoudt LW, Commandeur JNM, Vermeulen NPE. 1999 Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 29:59-124.
129. Wrightom SA, Stevens JC. 1992. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
130. Wrighton SA, VandenBranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, Cashman JR. 1993. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 25:453-484.
131. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, Shimada T. 1998. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidations of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 56:243-251.
132. Yun C-H, Okerholm RA, Guengerich FP. 1993. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P450 3A(4)in N-dealkylation and C-hydroxylation. Drug Metab Disp 21:403-409.
133. Zhou BP, Lewis DA, Kwan SW, Abell CW. 1995. Flavinylation of monoamine oxidase B. J Biol Chem 270:23653-23660.